| Name | PD 168368 |
| Description | PD 168368 is a novel, potent, competitive and selective nonpeptide neuromodulin B receptor (NMB-R) antagonist with inhibitory effects on the gastrin-releasing peptide receptor (GRPR).PD 168368 is a potent mixed agonist of FPR1/FPR2/FPR3. |
| In vitro | PD 168368 exhibits high activity and induces [Ca2+]I release in human neutrophils, with EC50 values in the nanomolar range[3].
In the human breast cancer cell line MDA-MB-231, PD 168368 suppresses migration and invasion. It also reduces epithelial-mesenchymal transition (EMT) by upregulating E-cadherin and downregulating vimentin. At a concentration of 5 μM, PD 168368 inhibits migration and invasiveness in breast cancer cells[4].
Furthermore, at a concentration of 10 μM, PD 168368 suppresses the activation of the mTOR/p70S6K/4EBP1 and AKT/GSK-3β pathways in breast cancer cells[4]. |
| In vivo | In mice, PD 168368 potently inhibits the in vivo metastasis of breast cancer. Administered at a dose of 1.2 mg/kg through intraperitoneal injection for 30 days, PD 168368 effectively inhibits breast cancer metastasis[4]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 20 mg/mL (36.06 mM), Sonication is recommended.
DMF : 5 mg/mL (9.01 mM), Sonication is recommended.
|
| Keywords | PD-168368 | PD 168368 | BombesinReceptor | Bombesin Receptor |
| Inhibitors Related | Bag-1 | BA 1 acetate(183241-31-8 free base) | MK-5046 | ML-18 | Bombesin acetate(31362-50-2 free base) | kuwanon G | Kuwanon H | Litorin acetate(55749-97-8 Free base) | CD80-IN-3 | [D-Phe12]-Bombesin acetate | PD176252 | [D-Phe12,Leu14]-Bombesin acetate |
| Related Compound Libraries | Bioactive Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |
United States
